Study of lentinan's promotion on XELOX regimen's curative effects on advanced gastric cancer / 中国生化药物杂志

ABSTRACT

Objective To study lentinan’s promotion on XELOX regimen’s curative effects on advanced gastric cancer. Method Cases with advanced gastric cancer were divided into observation group and control group according their therapy method. The curative effects, side effects, WBC, lymphocyte subsets, NK cells and quality of life were compared. Results The difference of disease control rates in two groups were not significant (P=0.091). The incidences of side effects in observation group were significantlly lower than in control group (P<0.05). The observation group’s WBC, Lym, CD 3+, CD 4+, CD 8+, NK cells and quality of life were significantly higher than in control group(P<0.05). Conclusion Lentinan could significantly promote gastric cancer patients’immunity and lessen side effects. It can promote XELOX regimen’s curative effects on gastric cancer and improve quality of life.